Ruti Aga's Six Years: How a Forged Prescription Became a Bigger Offence Than the Injection

A half marathon in China in March. The race has no name anywhere. Neither does a winning time. No course profile, no start list, no wind reading. The ledger has gained one line only: a sample taken after that race tested positive for a prohibited substance. I have been keeping road-race results in a ledger for close to four decades, and this is the first time I have seen a victory recorded with the time box left entirely blank. A race without a name is easy to annul. A race without a time teaches us nothing—unless we read the blank itself. The timing booth taught me that precision is a kind of patience. In 2026, at the Dhaka SAF Games, I sat in the booth under the stand writing heat times, and that is where I learned the rule that has governed everything since: a number without its method beside it is an incomplete number. Hand or electronic, wind reading, lane draw. That one habit later became the spine of my national-record audits. In the Ruti Aga case, the method box is the emptiest box of all, and it is the box that tells us what this affair actually is. Because the confirmed facts, counted properly, produce a picture. Ruti Aga of Ethiopia is 32. She won the 2026 Tokyo Marathon and finished runner-up at three World Marathon Majors. After winning a half marathon in China in March, her sample showed methylprednisolone. A provisional suspension took effect on 10 September, and the total sanction is six years. A prescription was submitted explaining a knee complaint; it was written by a family member with no medical registration, who claimed to have used an old pad from a former workplace. The clinic flatly denied the claim. Two separate offences are hiding inside those four sentences, and the journalistic duty is to keep them apart. First, the competitive tier, because that is where most of the misreading will happen. One Major win and three Major runner-up finishes is an excellent career, but it is not the tier of the athlete around whom an event is built. She sits comfortably in the global top 15 to 25 of her generation: a regular podium presence, occasionally a winner, never the face of the discipline. That distinction is economic as well as sporting. A top-tier marathoner earns largely from global endorsement; a second-tier elite earns largely from appearance fees, podium bonuses and race-to-race prize money. The ban, in her case, is close to total rather than marginal. Second, the pharmacology. Methylprednisolone is a glucocorticoid, an anti-inflammatory—precisely the drug class a marathoner with a knee complaint would be given. Under the WADA framework, glucocorticoids are prohibited in competition by injectable, oral or rectal routes; out of competition they are generally not. That single sentence is the centre of the case. A legitimate, documented out-of-competition injection, cleared in advance where needed by a therapeutic use exemption, is a defensible situation. A detectable in-competition presence is not. The question that matters here is not whether she cheated. The question is when the injection was given, and whose job it was to keep that calendar. For a glucocorticoid the prohibition window is narrow, and that window follows a doctor's diary, not an athlete's race schedule. Someone with working knowledge of the TUE process does not fall into this trap. Someone without it does. Third, and here the case turns—the medical channel. The prescription was written by a family member who holds no medical registration, who said he had used an old pad from a former workplace, which the clinic denied. This is not the story of a family accident. It is a specimen of a structural failure. What surrounds a second-tier African road runner is usually a personal coach, a manager-agent, a few training partners and relatives. What is usually absent is a licensed, registered, TUE-literate team physician. So when injury arrives, the most trusted person nearby becomes 'the doctor', and the paperwork becomes part of household management. Every number in the ledger is a witness, not a verdict. The heaviest witness here is not six but four. The structure of the analysis indicates that four of the six years come from tampering with the doping-control process, with the remainder attached to the underlying violation. The source records no prior sanction history, which means this is not a repeat-offender escalation. Six years arrived largely because a document was forged. That deserves a pause. Anti-doping publicly says it controls substances. In this case, the largest penalty was imposed while controlling paper. If the injection genuinely was for a knee, then what sank her was the attempt to build a credible explanation for it. The system punished a particular method of self-defence. To understand why this happens, look at the testing architecture of road racing. The March half marathon was a label race—appearance-fee driven, well outside the routine scrutiny of the Diamond League circuit, with the testing footprint set by the local national anti-doping organisation plus targeted Athletics Integrity Unit work rather than by the race's commercial profile. For a second-tier elite, this is familiar risk terrain: high fee, low surveillance. Here is my largest hesitation. Some will say she was caught, therefore the system worked. The system worked only because a sample was taken. The real question is why that sample was taken, and how many comparable races go untested. In the economics of label racing, both organiser and athlete feel the cost of testing. Where the race does not even have a public name, who is keeping the surveillance ledger? The annulment matters for the same reason. The March half marathon result will be disqualified—title, prize money, ranking points. The 2026 Tokyo title is untouched by this decision. There is a logic in that asymmetry: sanctions look forward, not back. But in my ledger two lines now separate—one a Major win, one an unnamed half marathon, with a question mark between them. There is another calculation nobody is running yet. The women's marathon competitive window is long—roughly 27 to 33, with outliers past 35. A six-year sanction at 32 means a return at 38. On paper, a return is not impossible. In practice, six years outside the competitive and testing system means separation from the elite training group, the agent network, the race invitations. In an event where podium margins are measured in minutes, a six-year gap is measured in careers. I do not predict matches. I weigh the silence between the odds. The silence speaking loudest in this case is the silence of the medical file. The message of six years is clear: an athlete who submits a false prescription will be punished more for the paper than for the drug. But does that message deter anyone? For an athlete with no access to a licensed physician, the ruling offers no answer about what to do next time. Now the angle that will be least discussed. The sympathy story is wrong, and the 'caught at last' story is incomplete. The truth is that this kind of case is not random—it is a predictable failure. In a system that gives a second-tier road runner no licensed medical support but verifies his paperwork closely enough to impose four years, this case will recur. Only the name and the country will change. Second, correlation and causation must not be blended. The presence of methylprednisolone proves the drug was in her body; it does not prove an intent to enhance performance. A glucocorticoid reduces inflammation and pain—that fits marathon recovery, not oxygen delivery. But the forged pad proves something else: someone believed the document would survive verification. Those two proofs do not weigh the same, and the sanction did not weigh them the same either. Third, the question is infrastructure, not character. Ethiopia's highland marathon pipeline is the densest talent reserve in the world—the camps of Addis Ababa, Sululta and Asella. In those camps coaching improves and competition improves, but medical literacy and document management do not. Talent is produced, and amateur medical practice stands beside it. That gap is not one person's failure; it is an industry's irregular hiring. I have kept the card index long after the screens arrived, since 2026, because a ledger shows what is consistent and what is merely sudden. In Ruti Aga's ledger I see a consistent podium career and, at the end of it, a sudden document. An athlete who finishes runner-up at three Majors in a row has method behind her results; people without method do not do that three times. The question is not her ability. It is the management around her. An old road-racing problem returns here—incomparability. There is no wind gauge on the road; course elevation, gradient, women-only or mixed pacing and the super-shoe era all shape a mark. Her best marks of 2026 and 2026 sit partly inside the first generation of carbon-plate advantage. Without course-level data, a full shoe-era deduction cannot be made. The last sprint gold was timed by hand; I still trust the hand, but I do not put a hand-timed mark and an electronic mark on the same line of the same page. Same rule here: no mark without its method. What is genuinely new in this case is the relocation of the sanction's centre of gravity. In the popular imagination of anti-doping, punishment comes from the injection. This case shows the larger share coming from the explanation of the injection. The consequence is that the biggest risk to an athlete is no longer failing to memorise the prohibited list—it is failing to produce a correct medical file. An athlete who cannot complete a TUE form in English is far more likely to be found culpable in the same set of facts. The counter-argument deserves airing: a forged document cannot be excused. If a fake prescription draws a light sanction, then tomorrow every positive case will arrive with a family-written note. The system needed a hard precedent, and it has one. My objection is not to the severity but to the distribution. A system that provides no medical support yet spends four years on the truthfulness of medical documents does not create deterrence—it creates caution. And caution only works for those who already have the right support. From four decades beside the track, in the timing booth, in the stand, and now at a desk in Khulna, one thing keeps returning: athletes are punished for what they did not think of, and are never trained in what they should have thought of. Aga's thought—that pain needed an explanation—was reasonable. The thing she did not think of, that the paper would be verified, is what sank her. Looking forward, the things to watch are not headlines but specific indicators. The next season's entry lists, and at what level she returns, if at all. The Athletics Integrity Unit's testing pattern, and whether out-of-competition testing expands into label races or stays as it was. Her agent and management structure, and whether the same names reappear. And whether the Ethiopian federation or the camp system introduces any formal medical-literacy provision. I do not predict. I only write it in the ledger—because the case that has just produced the heaviest sanction on record in this corner of the sport was not a prohibited-substance case. It was a prescription-pad case. And the question nobody is asking is this: if a prescription pad can cost six years, where are the six years held for the athlete who has no one able to write a legitimate one?